1. Home
  2. AFJK vs INKT Comparison

AFJK vs INKT Comparison

Compare AFJK & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AFJK
  • INKT
  • Stock Information
  • Founded
  • AFJK 2023
  • INKT 2017
  • Country
  • AFJK United States
  • INKT United States
  • Employees
  • AFJK N/A
  • INKT N/A
  • Industry
  • AFJK
  • INKT Medicinal Chemicals and Botanical Products
  • Sector
  • AFJK
  • INKT Health Care
  • Exchange
  • AFJK NYSE
  • INKT Nasdaq
  • Market Cap
  • AFJK 68.3M
  • INKT 75.7M
  • IPO Year
  • AFJK 2023
  • INKT 2021
  • Fundamental
  • Price
  • AFJK $11.17
  • INKT $18.56
  • Analyst Decision
  • AFJK
  • INKT Hold
  • Analyst Count
  • AFJK 0
  • INKT 3
  • Target Price
  • AFJK N/A
  • INKT $37.50
  • AVG Volume (30 Days)
  • AFJK 4.2K
  • INKT 2.9M
  • Earning Date
  • AFJK 01-01-0001
  • INKT 08-12-2025
  • Dividend Yield
  • AFJK N/A
  • INKT N/A
  • EPS Growth
  • AFJK N/A
  • INKT N/A
  • EPS
  • AFJK 0.23
  • INKT N/A
  • Revenue
  • AFJK N/A
  • INKT N/A
  • Revenue This Year
  • AFJK N/A
  • INKT N/A
  • Revenue Next Year
  • AFJK N/A
  • INKT N/A
  • P/E Ratio
  • AFJK $48.43
  • INKT N/A
  • Revenue Growth
  • AFJK N/A
  • INKT N/A
  • 52 Week Low
  • AFJK $10.24
  • INKT $4.56
  • 52 Week High
  • AFJK $11.25
  • INKT $76.00
  • Technical
  • Relative Strength Index (RSI)
  • AFJK N/A
  • INKT 51.35
  • Support Level
  • AFJK N/A
  • INKT $18.54
  • Resistance Level
  • AFJK N/A
  • INKT $21.50
  • Average True Range (ATR)
  • AFJK 0.00
  • INKT 8.00
  • MACD
  • AFJK 0.00
  • INKT -0.82
  • Stochastic Oscillator
  • AFJK 0.00
  • INKT 16.51

About AFJK AIMEI HEALTH TECHNOLOGY CO LTD

Aimei Health Technology Co Ltd is a blank check company.

About INKT MiNK Therapeutics Inc.

MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.

Share on Social Networks: